Joan Brugge, Ph.D.
Joan Brugge, Ph.D.
Louise Foote Pfeiffer Professor of Cell Biology (HMS)
Director of the Ludwig Center at Harvard
C-513C
617-432-3974
Brugge Lab

Joan Brugge, Ph.D., received her Ph.D. in virology from Baylor College of Medicine, and was a postdoctoral researcher at the University of Colorado Medical Center. After professorships at SUNY, Stony Brook and the University of Pennsylvania, where she was an HHMI investigator, she became the Scientific Director and Senior VP at ARIAD Pharmaceuticals. She returned to academia as Professor of Cell Biology at HMS in 1997, and was Chair of the department from 2004-2014. She became Co-Director of the Ludwig Center at Harvard in 2014. She currently sits on the Scientific Advisory Board of the Allen Institute of Cell Sciences.

The Brugge laboratory is investigating the cellular processes and pathways that are involved in normal morphogenesis of epithelial tissues as well as those involved in the initiation and progression of epithelial tumors.

Harvard Medical School

Dept. of Cell Biology, C-513B

240 Longwood Avenue

Boston, MA 02115

Lab phone: 617-432-3974

Lab fax: 617-432-3969

 

Faculty Assistant

Long-term culture, genetic manipulation and xenotransplantation of human normal and breast cancer organoids.
Authors: Authors: Dekkers JF, van Vliet EJ, Sachs N, Rosenbluth JM, Kopper O, Rebel HG, Wehrens EJ, Piani C, Visvader JE, Verissimo CS, Boj SF, Brugge JS, Clevers H, Rios AC.
Nat Protoc
View full abstract on Pubmed
Aging-Associated Alterations in Mammary Epithelia and Stroma Revealed by Single-Cell RNA Sequencing.
Authors: Authors: Li CM, Shapiro H, Tsiobikas C, Selfors LM, Chen H, Rosenbluth J, Moore K, Gupta KP, Gray GK, Oren Y, Steinbaugh MJ, Guerriero JL, Pinello L, Regev A, Brugge JS.
Cell Rep
View full abstract on Pubmed
Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines.
Authors: Authors: Zhao W, Li J, Chen MM, Luo Y, Ju Z, Nesser NK, Johnson-Camacho K, Boniface CT, Lawrence Y, Pande NT, Davies MA, Herlyn M, Muranen T, Zervantonakis IK, von Euw E, Schultz A, Kumar SV, Korkut A, Spellman PT, Akbani R, Slamon DJ, Gray JW, Brugge JS, Lu Y, Mills GB, Liang H.
Cancer Cell
View full abstract on Pubmed
3D Culture Models with CRISPR Screens Reveal Hyperactive NRF2 as a Prerequisite for Spheroid Formation via Regulation of Proliferation and Ferroptosis.
Authors: Authors: Takahashi N, Cho P, Selfors LM, Kuiken HJ, Kaul R, Fujiwara T, Harris IS, Zhang T, Gygi SP, Brugge JS.
Mol Cell
View full abstract on Pubmed
Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer.
Authors: Authors: Zoeller JJ, Vagodny A, Daniels VW, Taneja K, Tan BY, DeRose YS, Fujita M, Welm AL, Letai A, Leverson JD, Blot V, Bronson RT, Dillon DA, Brugge JS.
Breast Cancer Res
View full abstract on Pubmed
Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07).
Authors: Authors: Hurvitz SA, Caswell-Jin JL, McNamara KL, Zoeller JJ, Bean GR, Dichmann R, Perez A, Patel R, Zehngebot L, Allen H, Bosserman L, DiCarlo B, Kennedy A, Giuliano A, Calfa C, Molthrop D, Mani A, Chen HW, Dering J, Adams B, Kotler E, Press MF, Brugge JS, Curtis C, Slamon DJ.
Nat Commun
View full abstract on Pubmed
Transient commensal clonal interactions can drive tumor metastasis.
Authors: Authors: Naffar-Abu Amara S, Kuiken HJ, Selfors LM, Butler T, Leung ML, Leung CT, Kuhn EP, Kolarova T, Hage C, Ganesh K, Panayiotou R, Foster R, Rueda BR, Aktipis A, Spellman P, Ince TA, Xiu J, Oberley M, Gatalica Z, Navin N, Mills GB, Bronson RT, Brugge JS.
Nat Commun
View full abstract on Pubmed
Fibroblast-tumor cell signaling limits HER2 kinase therapy response via activation of MTOR and antiapoptotic pathways.
Authors: Authors: Zervantonakis IK, Poskus MD, Scott AL, Selfors LM, Lin JR, Dillon DA, Pathania S, Sorger PK, Mills GB, Brugge JS.
Proc Natl Acad Sci U S A
View full abstract on Pubmed
Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer.
Authors: Authors: Shu S, Wu HJ, Ge JY, Zeid R, Harris IS, Jovanovic B, Murphy K, Wang B, Qiu X, Endress JE, Reyes J, Lim K, Font-Tello A, Syamala S, Xiao T, Reddy Chilamakuri CS, Papachristou EK, D'Santos C, Anand J, Hinohara K, Li W, McDonald TO, Luoma A, Modiste RJ, Nguyen QD, Michel B, Cejas P, Kadoch C, Jaffe JD, Wucherpfennig KW, Qi J, Liu XS, Long H, Brown M, Carroll JS, Brugge JS, Bradner J, Michor F, Polyak K.
Mol Cell
View full abstract on Pubmed
Organoid cultures from normal and cancer-prone human breast tissues preserve complex epithelial lineages.
Authors: Authors: Rosenbluth JM, Schackmann RCJ, Gray GK, Selfors LM, Li CM, Boedicker M, Kuiken HJ, Richardson A, Brock J, Garber J, Dillon D, Sachs N, Clevers H, Brugge JS.
Nat Commun
View full abstract on Pubmed